KR20200057701A - 수의과용 igg fc 변이체 - Google Patents

수의과용 igg fc 변이체 Download PDF

Info

Publication number
KR20200057701A
KR20200057701A KR1020207005513A KR20207005513A KR20200057701A KR 20200057701 A KR20200057701 A KR 20200057701A KR 1020207005513 A KR1020207005513 A KR 1020207005513A KR 20207005513 A KR20207005513 A KR 20207005513A KR 20200057701 A KR20200057701 A KR 20200057701A
Authority
KR
South Korea
Prior art keywords
seq
polypeptide
amino acid
igg
acid substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020207005513A
Other languages
English (en)
Korean (ko)
Inventor
항준 장
람 누엔
용종 리
펀 치안
샤이어 지안 리
Original Assignee
킨드레드 바이오사이언시스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65361820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20200057701(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 킨드레드 바이오사이언시스, 인코포레이티드 filed Critical 킨드레드 바이오사이언시스, 인코포레이티드
Publication of KR20200057701A publication Critical patent/KR20200057701A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020207005513A 2017-08-15 2018-08-15 수의과용 igg fc 변이체 Pending KR20200057701A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545858P 2017-08-15 2017-08-15
US62/545,858 2017-08-15
PCT/IB2018/056142 WO2019035010A1 (en) 2017-08-15 2018-08-15 IGG VARIANTS FOR VETERINARY USE

Publications (1)

Publication Number Publication Date
KR20200057701A true KR20200057701A (ko) 2020-05-26

Family

ID=65361820

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207005513A Pending KR20200057701A (ko) 2017-08-15 2018-08-15 수의과용 igg fc 변이체

Country Status (10)

Country Link
US (1) US12297272B2 (enExample)
EP (1) EP3668536A4 (enExample)
JP (2) JP2020531002A (enExample)
KR (1) KR20200057701A (enExample)
CN (2) CN119390821A (enExample)
AU (3) AU2018318440A1 (enExample)
BR (1) BR112020002871A2 (enExample)
CA (1) CA3071337A1 (enExample)
MX (1) MX2020001707A (enExample)
WO (1) WO2019035010A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017371217B2 (en) 2016-12-09 2020-03-19 Akston Biosciences Corporation Insulin-Fc fusions and methods of use
JP2020531002A (ja) 2017-08-15 2020-11-05 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学用ｉｇｇ ｆｃ変異体
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CN113038964B (zh) 2018-06-29 2025-05-27 德克拉有限公司 超长效胰岛素-fc融合蛋白及使用方法
BR112021006977A2 (pt) * 2018-10-18 2021-07-27 Kindred Biosciences, Inc. variantes fc com ligação alterada a receptor fc neonatal (fcrn) para uso veterinário
AU2019416344A1 (en) * 2018-12-27 2021-07-01 Elanco Us Inc. IgG Fc variants for veterinary use
AU2020205073A1 (en) 2019-01-03 2021-08-19 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
WO2020191289A1 (en) * 2019-03-20 2020-09-24 Kindred Biosciences, Inc. Ngf antagonists for medical use
MX2022001104A (es) * 2019-07-30 2022-02-14 Kindred Biosciences Inc Anticuerpos de parvovirus para uso veterinario.
DK4073098T5 (da) 2019-12-19 2024-07-22 Akston Biosciences Corp Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
JP2023513952A (ja) 2020-02-19 2023-04-04 アディボ ゲーエムベーハー 改変Ｆｃ領域
MX2022011335A (es) * 2020-03-18 2022-10-07 Kindred Biosciences Inc Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
US11213581B2 (en) 2020-04-10 2022-01-04 Akston Biosciences Corporation Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
GB202005879D0 (en) 2020-04-22 2020-06-03 Petmedix Ltd Heterodimeric proteins
CA3173864A1 (en) * 2020-04-22 2021-10-28 Shyr Jiann Li Long-acting anti-il31 antibodies for veterinary use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CA3178123A1 (en) 2020-05-11 2021-11-18 William Brondyk Compositions for increasing half-life of a therapeutic agent in canines and methods of use
WO2022010652A1 (en) 2020-07-10 2022-01-13 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
CA3190396A1 (en) * 2020-08-24 2022-03-03 James M. Wilson Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines
CN112625093B (zh) * 2020-12-29 2022-12-23 清远市图微安创科技开发有限公司 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
EP4380974A1 (en) * 2021-08-06 2024-06-12 Petmedix Ltd. Antibody fc variants
WO2024145280A2 (en) 2022-12-27 2024-07-04 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
KR20250151402A (ko) 2023-01-20 2025-10-21 인베티엑스 인코포레이티드 반려 동물에서 사용하기 위한 이중특이적 결합제
GB202311984D0 (en) * 2023-08-04 2023-09-20 Petmedix Ltd Optimised fc molecules
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions
WO2026039359A1 (en) * 2024-08-12 2026-02-19 Akston Biosciences Corporation Fc fusion protein therapeutics for companion animal obesity and methods of use
WO2026038455A1 (ja) * 2024-08-14 2026-02-19 国立大学法人山口大学 細胞傷害活性及び細胞貪食活性を低減させた抗ネコ抗体

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6207383B1 (en) * 1998-07-27 2001-03-27 University Of Utah Research Foundation Mutations in and genomic structure of HERG—a long QT syndrome gene
US7297482B2 (en) * 1998-10-08 2007-11-20 Rigel Pharmaceuticals, Inc. Structurally biased random peptide libraries based on different scaffolds
AU2511901A (en) * 1999-12-23 2001-07-09 Universite De Geneve Basolateral sorting signal and inhibitors thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JP2004321100A (ja) 2003-04-25 2004-11-18 Rikogaku Shinkokai ＩｇＧのＦｃ領域を含むタンパク質の変異体
EA008831B1 (ru) 2003-06-12 2007-08-31 Эли Лилли Энд Компани Слитые белки аналогов glp-1
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0519393A2 (pt) 2004-12-22 2009-01-20 Lilly Co Eli formulaÇço em soluÇço estÁvel
US20100104564A1 (en) 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
WO2007012188A1 (en) 2005-07-27 2007-02-01 Qinghua Wang GLP/1/EXENDM 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
KR20100021601A (ko) * 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
US20100196405A1 (en) 2007-07-10 2010-08-05 Kingman Ng GLP-1 Fc FUSION PROTEIN FORMULATION
BRPI0918204A2 (pt) * 2008-12-23 2015-12-08 Genentech Inc igv variante composição farmaceutica e kit
JP2012521784A (ja) 2009-03-30 2012-09-20 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲーエムバーハー イヌＦｃ部分を含む融合タンパク質
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
MX341925B (es) 2010-03-29 2016-09-07 Zymeworks Inc Anticuerpos con funcion efectora suprimida o mejorada.
WO2012020096A1 (en) 2010-08-13 2012-02-16 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
ES2704007T3 (es) 2011-05-06 2019-03-13 Nexvet Australia Pty Ltd Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos
CA2835094C (en) 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
EP2537864B1 (en) * 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
CN103930134B (zh) 2011-07-18 2016-12-21 阿茨生物股份有限公司 长效促黄体激素(lh)化合物
CN104583415B (zh) 2011-07-19 2018-04-03 国家生物技术研究所公司 新型il‑17r‑ecd突变体
WO2013063186A2 (en) 2011-10-26 2013-05-02 Novartis Animal Health Us, Inc. Monoclonal antibodies and methods of use
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
US9731007B2 (en) * 2012-02-22 2017-08-15 Nexvet Australia Pty Ltd Tumour necrosis factor receptor fusion proteins and methods of using the same
WO2013165690A1 (en) 2012-04-30 2013-11-07 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
WO2014022592A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
WO2014093387A1 (en) 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
MX2016001165A (es) 2013-07-31 2016-06-29 Amgen Inc Estabilizacion de polipeptidos que contienen fragmentos cristalizables.
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
CA2932515C (en) 2013-12-20 2023-08-01 Intervet International B.V. Caninized antibodies
CN106456745A (zh) 2014-02-11 2017-02-22 北京艾棣维欣生物技术有限公司 具有白细胞介素‑17作为佐剂的疫苗
EP3194440A1 (en) 2014-09-15 2017-07-26 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
EP3201230B1 (en) 2014-09-30 2020-12-23 Intervet International B.V. Pd-l1 antibodies binding canine pd-l1
EP3215524B1 (en) 2014-11-06 2021-01-13 F.Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and protein a-binding properties
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
KR20170129902A (ko) 2015-03-23 2017-11-27 조운스 테라퓨틱스, 인크. Icos에 대한 항체
IL257723B2 (en) 2015-10-19 2023-04-01 Novartis Ag Methods for the treatment of non-radiographic sclerosing spondylitis with the help of interleukin-17 (il-17) antagonists
WO2017102920A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
RU2738265C2 (ru) 2016-01-26 2020-12-11 Дефенсин Терапьютикс Апс Способы модуляции кишечной микробиоты
WO2017142800A1 (en) 2016-02-18 2017-08-24 Eli Lilly And Company Chimeric canine anti-cd20 antibody
JP7632835B2 (ja) 2016-05-20 2025-02-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 加齢関連疾患及び症状の遺伝子治療法
US20180009869A1 (en) 2016-07-08 2018-01-11 AskGene Pharma, Inc. Fusion Protein Comprising Leptin and Methods for Producing and Using the Same
EP3526246A1 (en) 2016-10-17 2019-08-21 Vetoquinol SA Modified antibody constant region
CA3045797A1 (en) 2016-12-02 2018-06-07 The Texas A&M University System Fusion proteins for selectively depleting antigen-specific antibodies
BR112019021812A2 (pt) * 2017-04-21 2020-05-26 Kindred Biosciences, Inc. Molécula receptora de il4/il13 para uso veterinário
US11299540B2 (en) 2017-06-18 2022-04-12 Kindred Biosciences, Inc. IL17A antibodies and antagonists for veterinary use
JP2020531002A (ja) 2017-08-15 2020-11-05 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学用ｉｇｇ ｆｃ変異体
CN113038964B (zh) 2018-06-29 2025-05-27 德克拉有限公司 超长效胰岛素-fc融合蛋白及使用方法
JP2022500037A (ja) 2018-09-14 2022-01-04 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための抗ｉｌ４受容体抗体
BR112021006977A2 (pt) 2018-10-18 2021-07-27 Kindred Biosciences, Inc. variantes fc com ligação alterada a receptor fc neonatal (fcrn) para uso veterinário
WO2020086886A1 (en) 2018-10-25 2020-04-30 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
US12351622B2 (en) 2018-12-05 2025-07-08 Bica Therapeutics Inc. Modified product of Fc domain of antibody
CA3121586A1 (en) 2018-12-12 2020-06-18 Kindred Biosciences, Inc. Erythropoietin analogs for veterinary use
AU2019416344A1 (en) 2018-12-27 2021-07-01 Elanco Us Inc. IgG Fc variants for veterinary use
AU2020205073A1 (en) 2019-01-03 2021-08-19 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
WO2020191289A1 (en) 2019-03-20 2020-09-24 Kindred Biosciences, Inc. Ngf antagonists for medical use
KR20220066276A (ko) 2019-08-22 2022-05-24 시다라 세라퓨틱스, 인코포레이티드 변이체 fc 도메인 및 이의 용도
CN114364796B (zh) 2019-09-02 2023-07-11 甘李药业股份有限公司 嵌合蛋白
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP4136109A1 (en) 2020-04-17 2023-02-22 Zoetis Services LLC Feline antibody variants
PH12022552742A1 (en) 2020-04-17 2024-03-25 Zoetis Services Llc Canine antibody variants
US20240270819A1 (en) 2020-04-22 2024-08-15 Elanco Us Inc. Il4/il13 receptor molecules for veterinary use
CA3173864A1 (en) 2020-04-22 2021-10-28 Shyr Jiann Li Long-acting anti-il31 antibodies for veterinary use
CA3178123A1 (en) 2020-05-11 2021-11-18 William Brondyk Compositions for increasing half-life of a therapeutic agent in canines and methods of use
WO2021251438A1 (ja) 2020-06-10 2021-12-16 株式会社バイカ・セラピュティクス エリスロポエチンポリペプチドを含む融合タンパク質
US20230250155A1 (en) 2020-06-29 2023-08-10 Zoetis Services Llc Feline antibody variants for improving stability
WO2022010652A1 (en) 2020-07-10 2022-01-13 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
EP4204013A4 (en) 2020-08-26 2025-04-16 Angiex, Inc. ANTIMITOTIC TETRAPEPTIDE-ANTIBODY CONJUGATES AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
JP2020531002A (ja) 2020-11-05
CN111182915A (zh) 2020-05-19
AU2025220819A1 (en) 2025-09-25
CN119390821A (zh) 2025-02-07
US12297272B2 (en) 2025-05-13
JP2026048634A (ja) 2026-03-17
EP3668536A1 (en) 2020-06-24
AU2023226676B2 (en) 2025-05-22
EP3668536A4 (en) 2021-05-26
WO2019035010A1 (en) 2019-02-21
BR112020002871A2 (pt) 2020-07-28
RU2020110584A (ru) 2021-09-17
RU2020110584A3 (enExample) 2021-12-15
AU2023226676A1 (en) 2023-09-28
CA3071337A1 (en) 2019-02-21
US20200362034A1 (en) 2020-11-19
AU2018318440A1 (en) 2020-02-13
MX2020001707A (es) 2020-03-20

Similar Documents

Publication Publication Date Title
US12297272B2 (en) IgG Fc variants for veterinary use
JP6960832B2 (ja) Ｆｇｆ２１突然変異体及びその使用
US8795985B2 (en) FGF 21 polypeptides comprising two or more mutations and uses thereof
JP7776461B2 (ja) 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
US20220169740A1 (en) NGF Antagonists for Medical Use
AU2010246038A1 (en) FGF21 mutants and uses thereof
JP7821741B2 (ja) 動物用のｉｌ４／ｉｌ１３受容体分子
RU2814952C2 (ru) ВАРИАНТЫ IgG-FC ДЛЯ ПРИМЕНЕНИЯ В ВЕТЕРИНАРИИ
RU2829812C2 (ru) Антагонисты ngf для медицинского использования

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701